Regeneron R1979-ONC-1625

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Link

Ascentage APG-2575CU101

A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED)
Study Link

Antengene ATG-037-001
A Phase I/Ib, Multi-centre, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumours
Study Link

Ascendis ASND0029
TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies
Study Link

Hanmi HM-EZHI-101
A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients with Advanced or Metastatic Solid Tumors
Study Link

Iksuda IKS014-01
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors
Study Link

Eli Lilly LOXO-RAS-20001
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Study Link

Stingray SR-8541A-001
Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 inhibitor) Administered Orally as Monotherapy in Subjects with Advanced/Metastatic Solid Tumors
Study Link

Aulos CP-AU-007-01
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
Study Link

Seagen SGNDV-004
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors
Study Link

Hummingbird CRUKD/22/002
A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers
Study Link

Eikon EIK1003-001
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
Study Link

Bayer BAY 3498264 / 22676
Phase 1 study of a SOS1 inhibitor, BAY 3498264, in combination in participants with advanced KRASG12C-mutated solid tumors
Study Link

Adcendo ApS ADCE-T02-001
First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Study Link

AkesoBio AK138D1-101
A First-in-human, Phase I Study of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of AK138D1 in the treatment of advanced solid tumors
Study Link

EnGeneIC ENG19
An open-label, multicenter, Phase IIa study assessing the safety and efficacy of EGFR targeted EDVs carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying α-galactosyl ceramide in subjects with advanced EGFR-expressing cancers
Study Link

Domain DT-7012-CLI-001
A Phase 1/2a, multicentre, open-label clinical trial of DT-7012 in participants with advanced solid tumours
Study Link

Oncozen OZS001-101
A Phase 1, Open-label, First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumors with a Focus on Triple Negative Breast Cancer
Study Link

EIK1004-001 (IMP1707-101)
A Phase I/II, open-label, multicenter, dose-escalation, and dose-optimization study to evaluate the safety, tolerability, and activity of EIK1004 (IMP1707) as monotherapy in participants with advanced solid tumors
Study Link

LM299-01-102
A Phase I/II, open-label, dose escalation and dose expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of LM-299 injection as monotherapy or in combination with other anti-tumor therapies in patients with advanced solid tumors
Study Link

LM350-01-101
A Phase I/II, first-in-human (FIH), open-label, multicenter clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of LM-350 in patients with advanced solid tumors
Study Link

Boehringer Ingelheim BI 1456-0001
Phase I open-label, dose-escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors.
Study Link

Incyclix Bio INX-315-01
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients with Advanced Cancer
Study Link

ABL Bio ABL103-1002
A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination with Pembrolizumab with/without Taxane (Paclitaxel or nab-paclitaxel) in Subjects with Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
Study Link

VS-7375-101
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Study Link

Daiichi Sankyo DS1062-A-U303
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Study Link

Daiichi Sankyo DS1062-A-U304
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
Study Link

TheRas / BridgeBio TBBO8520-101
A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination with Pembrolizumab in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer – the ONKORAS-101 Study
Study Link

BioNTech BNT327-06
A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
Study Link

BioNTech BNT327-03
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer
Study Link

MCLA-158-CL04
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Combination with Docetaxel as Second-Line Treatment in Adults with Metastatic Non-Small Cell Lung Cancer or in Combination with Pembrolizumab as First-Line Treatment
Study Link

JAZZ JZP598-303
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
Study Link

BNT327-05
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
Study Link

Seagen RC48-G001

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma
Study Link

Seagen SGNDV-001

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
Study Link

Ractigen RAG-01-01

A phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) who have failed Bacillus Calmette Guérin (BCG) therapy
Study Link